Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Macitentan/Tadalafil FDC in Healthy Adults
NCT05236231Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Feb 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of macitentan + tadalafil in pulmonary arterial hypertension (PAH) (6 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Maximum Observed Plasma Analyte Concentration up to 216 hours, Area Under the Plasma Analyte Concentration Time Curve from Time Zero to Time of Last Quantifiable Concentration up to 216 hours and 1 more. Started Feb 2022; status: completed.
02
Drugs
macitentan + tadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05236231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05236231.